Self-replicating RNA SARS-CoV-2 Vaccine Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective and efficient vaccines against SARS-CoV-2, particularly those that can be produced in large quantities rapidly, as current methods like egg-based techniques for influenza vaccines are insufficient for pandemic responses.
Innovation Solution
Development of self-replicating RNA encoding SARS-CoV-2 antigens, specifically the spike and nucleocapsid proteins, linked to a subgenomic promoter, which can induce an immune response and be used as a vaccine to prevent or treat COVID-19 and related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional egg-based techniques are used for vaccine manufacturing, then existing infrastructure can be utilized, but production capacity is insufficient and development time is excessive for pandemic responses
Solution Approach 1:
The patent changes the fundamental parameter of vaccine delivery from traditional egg-based injection to inhalable RNA formulation. This parameter change enables direct delivery to respiratory epithelium, bypassing traditional manufacturing constraints and enabling rapid scale-up production while maintaining immunogenicity through localized immune activation in the respiratory tract
Solution Approach 2:
The patent uses synthetic RNA molecules as copies of viral antigens that can be rapidly produced through molecular biology techniques rather than traditional viral culture methods. This copying approach allows for quick replication of immunogenic sequences without requiring time-consuming viral propagation in eggs, significantly reducing development time while maintaining production capacity
2Reliability
If self-replicating RNA is used to encode SARS-CoV-2 antigens, then immune response is induced and vaccine efficacy is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent extracts the essential immunogenic function from complex viral systems and isolates it into simplified RNA molecules that encode only the necessary antigenic information. This extraction removes unnecessary viral complexity while retaining the core function of inducing protective immunity, thereby reducing manufacturing complexity without compromising vaccine efficacy
Solution Approach 2:
The patent employs synthetic RNA molecules that can be rapidly synthesized and discarded, replacing the need for complex, long-term viral culture systems. These short-lived RNA intermediaries are easy to manufacture through standard molecular biology techniques, significantly reducing the operational complexity and infrastructure requirements compared to traditional vaccine production methods
Data Source
AI summary
The present disclosure relates to self-replicating RNA encoding an antigen from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof. Specifically, the disclosure provides a self-replicating RNA or a monocistronic self-replicating RNA comprising a nucleotide sequence encoding an antigen operably linked to a subgenomic promoter, wherein the antigen is from SARS-CoV-2, and wherein the antigen is a Spike (S) protein or a nucleocapsid (N) protein.